IMPAACT 2032 Funded by the NIH to Evaluate Remdesivir for COVID-19 in Pregnancy

IMPAACT 2032 has opened to accrual to evaluate the effects of remdesivir in pregnant women who have been prescribed the drug to treat COVID-19. It aims to determine how pregnant women metabolize the drug and whether there are any potential side effects. The study will be conducted at 16 sites in the United States. The study is supported by NIAID and NICHD, with Gilead Sciences also providing funding to IMPAACT to support the study.

> READ THE NIH PRESS RELEASE